Literature DB >> 26674124

Efficient antigen delivery to the draining lymph nodes is a key component in the immunogenic pathway of the intradermal vaccine.

Miyuki Tozuka1, Tatsuya Oka1, Nao Jounai1, Gyohei Egawa2, Ken J Ishii3, Kenji Kabashima2, Fumihiko Takeshita4.   

Abstract

BACKGROUND: It has been clinically demonstrated that intradermal (ID) vaccines have a potential to confer a superior immunogenic profile compared to intramuscular (IM) or subcutaneous (SC) vaccines. In terms of distribution of a vaccine antigen depending on the administration routes, at least two independent immunogenic pathways of the vaccines have been proposed: (1) the antigen recognition by the immune cells present at the vaccine-administered site and (2) the antigen recognition by the lymph node (LN)-resident immune cells through the lymphatic flow from the vaccine-administered site after the antigen is directly delivered into the draining LNs.
OBJECTIVE: In order to clarify the key components for the immunogenic pathway of the ID vaccine, the correlation between the kinetics of the antigen distribution to the draining LNs and antibody responses to the antigen were evaluated.
METHODS: We compared the antibody responses in the groups with by surgical removal of the administration site immediately after the ID administration, and by surgical removal of the draining LNs before the ID administration.
RESULTS: The results suggested that the efficient and direct antigen delivery to the draining LNs plays an important role in the antibody responses to the ID vaccine. Indeed, it was confirmed that the direct administration into the draining LNs with the antigen elicited comparable levels of the antibody responses with the ID vaccine. At the cellular level, it was shown that the LN-resident immune cells such as B cells, dendritic cells, and macrophages including medullary macrophages and subcapsular sinus macrophages interacting with the antigens following the ID administration. Finally, we demonstrated by immunofluorescence analysis that the lymphatic vessels are more diffusely distributed in the dermis as compared with the subcutaneous area and muscle.
CONCLUSION: The results of the present study suggested that the skin is an optimal tissue to facilitate the vaccine antigen access to the draining LNs, which is an important immunogenic pathway of the ID vaccine. Further elucidation of regulatory mechanisms underlying such an immunogenic pathway of the ID vaccine would provide us with elements for the development of novel adjuvants and devices to enhance the immunogenicity of the ID vaccines.
Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Keywords:  Antigen delivery; Intradermal vaccine; Lymph nodes; Lymphatic vessels

Mesh:

Substances:

Year:  2015        PMID: 26674124     DOI: 10.1016/j.jdermsci.2015.11.008

Source DB:  PubMed          Journal:  J Dermatol Sci        ISSN: 0923-1811            Impact factor:   4.563


  12 in total

1.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

2.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

Review 3.  Fluzone® intra-dermal (Intanza®/Istivac® Intra-dermal): An updated overview.

Authors:  Nicola Luigi Bragazzi; Andrea Orsi; Filippo Ansaldi; Roberto Gasparini; Giancarlo Icardi
Journal:  Hum Vaccin Immunother       Date:  2016-05-31       Impact factor: 3.452

4.  Gliadin Nanoparticles Induce Immune Tolerance to Gliadin in Mouse Models of Celiac Disease.

Authors:  Tobias L Freitag; Joseph R Podojil; Ryan M Pearson; Frank J Fokta; Cecilia Sahl; Marcel Messing; Leif C Andersson; Katarzyna Leskinen; Päivi Saavalainen; Lisa I Hoover; Kelly Huang; Deborah Phippard; Sanaz Maleki; Nicholas J C King; Lonnie D Shea; Stephen D Miller; Seppo K Meri; Daniel R Getts
Journal:  Gastroenterology       Date:  2020-02-04       Impact factor: 22.682

5.  Real-Time Imaging of Vaccine Biodistribution Using Zwitterionic NIR Nanoparticles.

Authors:  Wataru Katagiri; Jeong Heong Lee; Marc-André Tétrault; Homan Kang; Sinyoung Jeong; Conor L Evans; Shinya Yokomizo; Sheena Santos; Catherine Jones; Shuang Hu; Georges El Fakhri; Kosuke Tsukada; Hak Soo Choi; Satoshi Kashiwagi
Journal:  Adv Healthc Mater       Date:  2019-06-05       Impact factor: 9.933

6.  Chemical Modulation of Bioengineered Exosomes for Tissue-Specific Biodistribution.

Authors:  Do Won Hwang; Min Joo Jo; Jeong Heon Lee; Homan Kang; Kai Bao; Shuang Hu; Yoonji Baek; Hyung Geun Moon; Dong Soo Lee; Satoshi Kashiwagi; Maged Henary; Hak Soo Choi
Journal:  Adv Ther (Weinh)       Date:  2019-09-13

7.  Intradermal Delivery of Antigens Enhances Specific IgG and Diminishes IgE Production: Potential Use for Vaccination and Allergy Immunotherapy.

Authors:  Takuwa Yasuda; Takehiro Ura; Masaru Taniguchi; Hisahiro Yoshida
Journal:  PLoS One       Date:  2016-12-14       Impact factor: 3.240

Review 8.  Determination of T Follicular Helper Cell Fate by Dendritic Cells.

Authors:  Jayendra Kumar Krishnaswamy; Samuel Alsén; Ulf Yrlid; Stephanie C Eisenbarth; Adam Williams
Journal:  Front Immunol       Date:  2018-09-27       Impact factor: 7.561

9.  Aminated nanomicelles as a designer vaccine adjuvant to trigger inflammasomes and multiple arms of the innate immune response in lymph nodes.

Authors:  Chanyoung Song; Hathaichanok Phuengkham; Sun-Young Kim; Min Sang Lee; Ji Hoon Jeong; Sung Jae Shin; Yong Taik Lim
Journal:  Int J Nanomedicine       Date:  2017-10-12

10.  New GMP manufacturing processes to obtain thermostable HIV-1 gp41 virosomes under solid forms for various mucosal vaccination routes.

Authors:  Mario Amacker; Charli Smardon; Laura Mason; Jack Sorrell; Kirk Jeffery; Michael Adler; Farien Bhoelan; Olga Belova; Mark Spengler; Beena Punnamoottil; Markus Schwaller; Olivia Bonduelle; Behazine Combadière; Toon Stegmann; Andrew Naylor; Richard Johnson; Desmond Wong; Sylvain Fleury
Journal:  NPJ Vaccines       Date:  2020-05-18       Impact factor: 7.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.